165 related articles for article (PubMed ID: 32469607)
1. Amorphous nano morin outperforms native molecule in anticancer activity and oral bioavailability.
Jangid AK; Agraval H; Gupta N; Jain P; Yadav UCS; Pooja D; Kulhari H
Drug Dev Ind Pharm; 2020 Jul; 46(7):1123-1132. PubMed ID: 32469607
[TBL] [Abstract][Full Text] [Related]
2. Morin hydrate loaded solid lipid nanoparticles: Characterization, stability, anticancer activity, and bioavailability.
Karamchedu S; Tunki L; Kulhari H; Pooja D
Chem Phys Lipids; 2020 Nov; 233():104988. PubMed ID: 33035545
[TBL] [Abstract][Full Text] [Related]
3. Designing of fatty acid-surfactant conjugate based nanomicelles of morin hydrate for simultaneously enhancing anticancer activity and oral bioavailability.
Jangid AK; Agraval H; Gupta N; Yadav UCS; Sistla R; Pooja D; Kulhari H
Colloids Surf B Biointerfaces; 2019 Mar; 175():202-211. PubMed ID: 30530006
[TBL] [Abstract][Full Text] [Related]
4. Enhanced biopharmaceutical performance of brick dust molecule nilotinib via stabilized amorphous nanosuspension using a facile acid-base neutralization approach.
Chougule M; Sirvi A; Saini V; Kashyap M; Sangamwar AT
Drug Deliv Transl Res; 2023 Oct; 13(10):2503-2519. PubMed ID: 37024611
[TBL] [Abstract][Full Text] [Related]
5. Fabrication of surfactant-stabilized nanosuspension of naringenin to surpass its poor physiochemical properties and low oral bioavailability.
Singh MK; Pooja D; Ravuri HG; Gunukula A; Kulhari H; Sistla R
Phytomedicine; 2018 Feb; 40():48-54. PubMed ID: 29496174
[TBL] [Abstract][Full Text] [Related]
6. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
7. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
8. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
[TBL] [Abstract][Full Text] [Related]
9. Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement.
Zawar LR; Bari SB
Recent Pat Drug Deliv Formul; 2018; 12(3):162-169. PubMed ID: 30003863
[TBL] [Abstract][Full Text] [Related]
10. Development and in vivo/in vitro evaluation of novel herpetrione nanosuspension.
Guo JJ; Yue PF; Lv JL; Han J; Fu SS; Jin SX; Jin SY; Yuan HL
Int J Pharm; 2013 Jan; 441(1-2):227-33. PubMed ID: 23220096
[TBL] [Abstract][Full Text] [Related]
11. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
[TBL] [Abstract][Full Text] [Related]
12. Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.
Alshweiat A; Csóka I; Tömösi F; Janáky T; Kovács A; Gáspár R; Sztojkov-Ivanov A; Ducza E; Márki Á; Szabó-Révész P; Ambrus R
Int J Pharm; 2020 Apr; 579():119166. PubMed ID: 32084574
[TBL] [Abstract][Full Text] [Related]
13. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
14. Development of nanosuspension formulation for oral delivery of quercetin.
Sun M; Gao Y; Pei Y; Guo C; Li H; Cao F; Yu A; Zhai G
J Biomed Nanotechnol; 2010 Aug; 6(4):325-32. PubMed ID: 21323105
[TBL] [Abstract][Full Text] [Related]
15. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar K; Shah J
Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
[TBL] [Abstract][Full Text] [Related]
16. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Nanosuspension Technology for Drug Delivery.
Arora D; Khurana B; Rath G; Nanda S; Goyal AK
Curr Pharm Des; 2018; 24(21):2403-2415. PubMed ID: 29788880
[TBL] [Abstract][Full Text] [Related]
18. Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
Mohapatra PK; Srivastava R; Varshney KK; Babu SH
Anticancer Agents Med Chem; 2022; 22(10):1984-2001. PubMed ID: 34353274
[TBL] [Abstract][Full Text] [Related]
19. Nanosuspension: A Formulation Technology for Tackling the Poor Aqueous Solubility and Bioavailability of Poorly Soluble Drugs.
Elsebay MT; Eissa NG; Balata GF; Kamal MA; Elnahas HM
Curr Pharm Des; 2023; 29(29):2297-2312. PubMed ID: 37694786
[TBL] [Abstract][Full Text] [Related]
20. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
Alsofany JM; Hamza MY; Abdelbary AA
AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]